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Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease 
worldwide, affecting approximately 25% of the population, and is quickly becoming 
the leading indication for liver transplantation (1).  NAFLD encompasses a spectrum 
of liver pathology from steatosis or non-alcoholic fatty liver (NAFL), to the 
inflammatory state of non-alcoholic steatohepatitis (NASH), and eventually to 
cirrhosis in a subset of patients (1).  
 
Pathophysiology 
 
Current evidence suggests the etiology of NAFLD is multifactorial and includes 
genetic factors, diet, a disturbance or imbalance in the gut microbiome known as 
dysbiosis, altered production of gut metabolites, gut luminal barrier dysfunction, 
and endothelial translocation of pro-inflammatory substances which results in 
hepatic inflammation (2). In some patients, an inflammatory cascade leads to 
histologic changes within the liver resulting in NASH, with recurrent insults and 
parenchymal remodeling resulting in hepatic fibrosis and cirrhosis (Figure 1).  
 
Gut Microbiome Dysbiosis in NAFLD 
 
The human gut microbiome is comprised mainly of bacteria, but also includes viral, 
fungal, and archaeal microorganisms (2). By utilizing 16S rRNA sequencing, it has 
been shown that two of the most abundant bacterial phyla of the gut microbiome 
are Bacteroidetes and Firmicutes (3). Human studies examining the alteration of the 
gut microbiome in patients with NAFLD and NASH compared to healthy controls 
have yielded significant heterogeneity. Children with biopsy-proven NASH or who 
were obese demonstrated a significant increase in the phylum of Bacteroidetes and 
a decrease in Firmicutes compared to healthy controls (4). However, similar results 
have not been found in adults. A study of obese adults with clinically suspected 
NAFLD showed there was no significant difference in the proportion of Firmicutes 
to Bacteroidetes between NAFLD and control groups (5). These results were 
replicated in patients with biopsy-proven NAFLD versus healthy controls with 
normal liver biopsies, although the relative abundance of Bacteroidetes was 
significantly lower in the NASH group (6). Among the small number of human 
studies that sequenced the microbiome of individuals with NAFLD there was 
significant variation of study designs, inclusion criteria, and conflicting results of 
bacterial abundance (Table 1). Nonetheless, the gut microbiome appears to be 
closely associated with the pathophysiology of NALFD development.  
 
Gut Microbiome Signature for Assessment of Liver Fibrosis in NAFLD 
 
The most feared complication of NAFLD is the progression to NASH and 
subsequently cirrhosis. The presence of advanced fibrosis is the most important 
predictor for liver-related events and complications in NAFLD (7). A novel method 
for non-invasive assessment of liver fibrosis in NAFLD using a gut microbiome-
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based metagenomics signature was recently published. The study sequenced the gut 
microbiome of 86 patients with biopsy-proven NAFLD. A total of 72 patients with 
stage 0-2 fibrosis were considered mild/moderate NAFLD and 14 patients with 
stage 3-4 fibrosis were considered advanced NAFLD. The phylum of Gram-positive 
Firmicutes was significantly higher in the mild/moderate NAFLD group, while 
Gram-n gative Proteobacteria was higher in the advanced fibrosis group. A trend 
toward an increase in Gram-negative bacteria in the advanced NAFLD group was 
also seen at the species level with an increase in Escherichia coli, albeit not 
statistically significant. A Random Forest (RF) model was generated using 37 
bacterial species with Shannon diversity, age, and BMI. The diagnostic accuracy for 
advanced NAFLD using this RF model had an impressive area under the curve (AUC) 
of 0.936 (7).  
 
Increased Intestinal Permeability 
 
The gastrointestinal epithelium forms a mechanical barrier separating the luminal 
contents, including the commensal organisms of the gut and their pro-inflammatory 
products, from the portal circulation, which provides the majority of the blood flow 
to the liver. One key factor in the development and progression of NAFLD is the 
integrity of the intestinal barrier, which is in part mediated by the microbiome.  A 
meta-analysis including 128 NAFLD patients showed that 39.1% of these patients 
had evidence for increased intestinal permeability based on urinary excretion of a 
measured compound compared to only 6.8% of healthy controls. In NASH patients, 
the percentage of individuals with increased intestinal permeability was even 
higher at 49.2% (8). It is unclear whether liver injury or compromise of the 
intestinal epithelium comes first, but nevertheless, current data supports a 
correlation between the two findings.    
 
Gut Translocation 
 
A compromised intestinal epithelium leads to translocation of potentially harmful 
substances derived from the gut microbiota into the portal circulation and directly 
to the liver. Lipopolysaccharide (LPS), also known as endotoxin, is derived from the 
cell wall of Gram-negative bacteria. Obese patients with biopsy-proven NASH were 
shown to have significantly higher levels of plasma IgG against endotoxin compared 
to obese patients with a normal liver biopsy. The levels of IgG also correlated with 
NASH severity on histology (9). Thus, chronic endotoxin exposure in patients with 
NAFLD appears to induce a pro-inflammatory cascade within the liver parenchyma 
that may contribute to the progression of NAFL to NASH and worsen the severity of 
NASH. 
 
Microbiome-Directed Therapy in NAFLD 
 
While it is unclear what specific gut bacterial milieu is most beneficial in preventing 
or perhaps reversing NAFLD, one therapeutic approach would be to restore gut 
homeostasis via manipulation of the gut microbiome through the use of probiotics. 
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A meta-analysis of four randomized trials with a total of 134 patients with NAFLD 
and NASH demonstrated that administration of probiotics resulted in significantly 
decreased levels of alanine aminotransferase, aspartate aminotransferase, total 
cholesterol, high-density lipoprotein, tumor necrosis factor-alpha, and homeostasis 
model assessment of insulin resistance, however, histologic assessments were not 
performed in any studies (10).  
 
Conclusion 
 
Current data suggests gut microbiome dysbiosis is closely related to the onset and 
progression of NAFLD through multiple mechanisms including disruption of the 
intestinal epithelial barrier and subsequent gut translocation of pro-inflammatory 
substances via the portal circulation to the liver. Studies that have sequenced the 
gut microbiome in patients with NAFLD demonstrate significant heterogeneity in 
their design and results, making data interpretation and generalizability difficult. 
While there is no clear predominant bacterium that mediates the development of 
NAFLD, utilizing the microbiome to identify individuals with NAFLD who have 
advanced fibrosis may allow for earlier clinical intervention. There appears to be a 
potential role for probiotics in clinical practice, perhaps as an adjunct to new 
emerging therapies. Further studies are clearly needed to elucidate the relationship 
between the gut microbiome and NAFLD. 
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Figure 1. Key factors and pathways involved in the establishment and progression of 
NAFLD to hepatic fibrosis. Genetics and a high-fat diet contribute to insulin 
resistance and an increase in plasma free fatty acids, which can lead to the 
development of the metabolic syndrome. These factors contribute to dysbiosis of 
the gut microbiome and increased gut epithelial permeability. The compromised 
intestinal barrier allows gut translocation of pro-inflammatory cytokines, ethanol 
produced from gut bacteria, and lipopolysaccharide (LPS) derived from the cell wall 
of Gram-negative bacteria. Delivery of gut-derived substances directly to the liver 
via the portal circulation results in an inflammatory cascade with resultant hepatic 
inflammation and development of non-alcoholic steatohepatitis (NASH) in some 
patients with NAFL. This results in hepatocyte death and activation of hepatic 
stellate cells, which leads to collagen deposition and subsequent liver fibrosis in a 
subset of patients with NASH.  
 
Table 1. Summary of studies examining the gut microbiome and its relationship to 
NAFLD and NASH. Abbreviations: BMI, body mass index; LFTs, liver function tests; 
NAFL, non-alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, non-
alcoholic steatohepatitis; US, ultrasound.    
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• Insulin resistance 
•  Free fatty acids 
 
Hepatic fibrosis 
 
• Hepatocyte death 
• Stellate cell activation 
• Collagen deposition 
 
• Gut dysbiosis 
• Increased gut permeability 
• Gut translocation 
• Genetics 
• High-fat diet 
• Metabolic syndrome 
Non-Alcoholic 
Steatohepatitis (NASH) 
 
Non-Alcoholic Fatty Liver (NAFL) 
 
• Pro-inflammatory cytokines 
• Lipopolysaccharide (LPS) 
• Ethanol 
Figure 1 
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Boursier et al., 2016 (11) Biopsy-proven: 
22 NAFL patients 
35 NASH patients 
  Bacteroides in NASH vs. NAFL 
     Prevotella in NASH vs. NAFL 
- Bacteroides abundance independently associated with NASH 
- Ruminococcus abundance independently associated with fibrosis F≥2 
Loomba et al., 2017 (9) 
 
 
 
 
86 Biopsy-proven NAFLD patients: 
(G1) 72 patients with stage 0-2 fibrosis 
(G2) 14 patients with stage 3-4 fibrosis 
 
 
 Bacteroidetes in G1 
 Proteobacteria in G2 
- Bacteroides vulgatus & Eubacterium rectale were most abundant 
species in G1 
- Bacteroides vulgatus & Escherichia coli were most abundant species 
in G2 
Raman et al., 2013 (5) 
 
30 NAFLD patients= elevated LFTs >1.5x 
normal, BMI >30, echogenic liver on US 30 
Control patients= BMI<25, normal LFTs 
 Lactobacillus in NAFLD vs. control 
 Oscillibacter, Robinsoniella, Roseburia, Doren in NAFLD vs. control 
- No difference in Bacteroides 
Spencer et al., 2011 (12) 15 Healthy female patients, BMI 18-34; 
given choline-deficient diet to induce fatty 
liver with stool samples before and after  
- No change in the abundance of any taxon at any point in the study  
- Each subject’s microbiome remained distinct throughout study course 
Wong et al., 2013 (13) 16 Patients with biopsy-proven NASH 
22 Control Patients= Normal LFTs, no 
chronic liver disease, BMI<25 
 Phylum Firmicutes in NASH vs. control 
 Parabacteroides & Allisonella in NASH vs. control 
      Faecalibacterium & Anaerosporobacter in NASH vs. control 
Zhu et al., 2013 (4) 22 children with biopsy-proven NASH 
25 obese children, BMI >95th percentile 
16 healthy controls, BMI <85th percentile 
 Phylum Bacteroidetes in obese and NASH vs. control 
     Phylum Firmicutes in obese & NASH vs. control 
 Enterobacteriaceae & Escherichia in NASH vs. obese 
Table 1 
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